Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oxford Biomedica plc (OXB.L)
GBp643.00
-6.00 (-0.92%)
GB LSE Healthcare Biotechnology
Address
Windrush Court OX4 6LT
Oxford, GB
Oxford, GB
CEO
Frank Mathias
Website
oxb.com
IPO
1996-12-13
ISIN GB00BDFBVT43
Description
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp643.00
-6.00 (-0.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
292.3K
Beta
1.10
Float Shares
66.76M
Free Float %
55.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.16% | +6.08% | +4.67% | -5.28% | -0.32% | +1.78% | +91.17% | +40.02% | -44.52% | +132.16% | -67.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
643.00
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.73
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+31.0% ★ Q4'25: +105.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+35.7% ★ Q4'25: +96.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-27.5% Q4'25: -11.6% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-19.9% Q4'25: -9.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-33.2% Q4'25: -23.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+8.2% Q4'25: +9.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.18× Q4'25: -2.85× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2000 actual |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 7 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 1 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
732.0K
est: 609.0K (+20.2%)
|
373.0K
est: 1.12M (-66.6%)
|
173.0K
est: 406.0K (-57.4%)
|
374.0K
est: 507.5K (-26.3%)
|
824.0K
est: 710.5K (+16.0%)
|
760.0K
est: 984.5K (-22.8%)
|
7.22M
est: 7.80M (-7.5%)
|
18.39M
est: 19.37M (-5.0%)
|
19.12M
est: 19.18M (-0.3%)
|
11.15M
est: 10.48M (+6.4%)
|
7.72M
est: 6.93M (+11.4%)
|
7.76M
est: 5.66M (+36.9%)
|
5.38M
est: 5.29M (+1.5%)
|
13.62M
est: 12.18M (+11.8%)
|
15.91M
est: 13.97M (+13.9%)
|
27.78M
est: 26.90M (+3.3%)
|
37.59M
est: 36.66M (+2.5%)
|
66.78M
est: 63.25M (+5.6%)
|
64.06M
est: 65.20M (-1.7%)
|
87.73M
est: 86.90M (+1.0%)
|
142.80M
est: 155.52M (-8.2%)
|
139.99M
est: 130.04M (+7.7%)
|
89.54M
est: 97.28M (-8.0%)
|
128.80M
est: 127.74M (+0.8%)
|
168.74M
est: 167.14M (+1.0%)
|
228.80M
222.65M – 234.79M
+36.9% YoY
|
289.06M
282.30M – 297.67M
+26.3% YoY
|
338.92M
338.92M – 338.92M
+17.3% YoY
|
414.48M
404.14M – 426.16M
+22.3% YoY
|
| EBITDA |
-5.56M
est: -111.0K (-4,911.5%)
|
-10.14M
est: -8.21M (-23.4%)
|
-12.66M
est: -2.60M (-386.4%)
|
-11.51M
est: -13.26M (+13.2%)
|
-9.59M
est: -18.57M (+48.4%)
|
-18.82M
est: -12.04M (-56.3%)
|
-17.40M
est: -135.85M (+87.2%)
|
-11.73M
est: -38.00M (+69.1%)
|
-4.78M
est: -9.82M (+51.3%)
|
-11.46M
est: -2.26M (-406.7%)
|
-13.51M
est: -6.96M (-94.0%)
|
-9.38M
est: -10.93M (+14.2%)
|
-11.70M
est: -8.64M (-35.4%)
|
-9.46M
est: -26.78M (+64.7%)
|
-13.46M
est: -11.79M (-14.2%)
|
-11.71M
est: -31.10M (+62.3%)
|
2.03M
est: -36.84M (+105.5%)
|
12.29M
est: -25.93M (+147.4%)
|
-9.60M
est: 446.0K (-2,252.9%)
|
3.92M
est: -26.16M (+115.0%)
|
33.22M
est: -37.76M (+188.0%)
|
-10.80M
est: -38.15M (+71.7%)
|
-148.62M
est: -22.46M (-561.6%)
|
-14.33M
est: -59.97M (+76.1%)
|
-33.54M
est: -38.59M (+13.1%)
|
-52.83M
-54.21M – -51.41M
-36.9% YoY
|
-66.75M
-68.73M – -65.18M
-26.3% YoY
|
-78.26M
-78.26M – -78.26M
-17.3% YoY
|
-95.71M
-98.40M – -93.32M
-22.3% YoY
|
| EBIT |
-5.93M
est: -179.8K (-3,199.1%)
|
-11.03M
est: -10.89M (-1.2%)
|
-13.88M
est: -4.01M (-246.0%)
|
-12.50M
est: -17.53M (+28.7%)
|
-10.28M
est: -24.54M (+58.1%)
|
-21.79M
est: -15.56M (-40.0%)
|
-20.14M
est: -167.24M (+88.0%)
|
-12.03M
est: -49.22M (+75.6%)
|
-5.07M
est: -13.34M (+62.0%)
|
-11.80M
est: -3.13M (-277.1%)
|
-14.29M
est: -7.94M (-80.0%)
|
-10.35M
est: -11.81M (+12.4%)
|
-12.76M
est: -9.80M (-30.1%)
|
-10.56M
est: -29.50M (+64.2%)
|
-15.09M
est: -12.67M (-19.1%)
|
-15.38M
est: -24.00M (+35.9%)
|
-2.35M
est: -16.27M (+85.6%)
|
11.24M
est: -10.91M (+203.1%)
|
-15.33M
est: 12.98M (-218.1%)
|
-5.70M
est: -17.63M (+67.7%)
|
20.77M
est: -25.44M (+181.6%)
|
-37.22M
est: -25.71M (-44.8%)
|
-177.33M
est: -31.32M (-466.1%)
|
-37.43M
est: -40.42M (+7.4%)
|
-33.54M
est: -53.81M (+37.7%)
|
-73.67M
-75.59M – -71.68M
-36.9% YoY
|
-93.07M
-95.84M – -90.89M
-26.3% YoY
|
-109.12M
-109.12M – -109.12M
-17.3% YoY
|
-133.45M
-137.21M – -130.12M
-22.3% YoY
|
| Net Income |
-5.00M
est: -169.92M (+97.1%)
|
-8.39M
est: -9.17M (+8.5%)
|
-11.66M
est: -3.05M (-282.2%)
|
-10.74M
est: -14.58M (+26.3%)
|
-9.09M
est: -20.41M (+55.5%)
|
-17.63M
est: -12.60M (-39.9%)
|
-15.29M
est: -139.74M (+89.1%)
|
-10.04M
est: -37.95M (+73.5%)
|
-3.52M
est: -9.80M (+64.1%)
|
-10.29M
est: -1.92M (-435.2%)
|
-12.63M
est: -6.80M (-85.7%)
|
-8.73M
est: -10.33M (+15.5%)
|
-11.10M
est: -8.16M (-36.0%)
|
-8.66M
est: -25.54M (+66.1%)
|
-13.02M
est: -10.34M (-25.9%)
|
-16.64M
est: -22.19M (+25.0%)
|
-9.02M
est: -23.93M (+62.3%)
|
7.54M
est: -17.35M (+143.5%)
|
-16.07M
est: 7.04M (-328.3%)
|
-6.25M
est: -19.58M (+68.1%)
|
19.01M
est: -28.26M (+167.3%)
|
-39.16M
est: -61.63M (+36.5%)
|
-157.49M
est: -157.88M (+0.2%)
|
-43.19M
est: -37.07M (-16.5%)
|
-30.13M
est: -30.13M (+0.0%)
|
-9.01M
-22.95M – -1.75M
+70.1% YoY
|
13.03M
7.42M – 18.64M
+244.6% YoY
|
42.46M
40.99M – 43.92M
+225.8% YoY
|
49.36M
47.76M – 51.17M
+16.2% YoY
|
| SGA |
—
est: 115.5K (-100.0%)
|
—
est: 211.8K (-100.0%)
|
3.42M
est: 77.0K (+4,341.3%)
|
2.92M
est: 96.3K (+2,935.7%)
|
2.87M
est: 134.8K (+2,026.0%)
|
2.70M
est: 186.7K (+1,345.4%)
|
4.28M
est: 1.48M (+189.3%)
|
3.84M
est: 10.62M (-63.8%)
|
6.06M
est: 3.75M (+61.6%)
|
3.92M
est: 3.31M (+18.4%)
|
3.81M
est: 2.59M (+47.1%)
|
3.62M
est: 3.12M (+16.2%)
|
3.42M
est: 3.38M (+1.2%)
|
3.96M
est: 7.87M (-49.7%)
|
6.74M
est: 4.72M (+42.7%)
|
5.96M
est: 11.49M (-48.1%)
|
7.28M
est: 8.56M (-15.0%)
|
7.43M
est: 14.00M (-46.9%)
|
11.88M
est: 6.94M (+71.3%)
|
11.26M
est: 14.48M (-22.2%)
|
15.15M
est: 20.90M (-27.5%)
|
28.22M
est: 21.11M (+33.7%)
|
25.41M
est: 20.19M (+25.9%)
|
29.42M
est: 26.61M (+10.5%)
|
36.76M
est: 34.69M (+6.0%)
|
47.49M
46.21M – 48.73M
+36.9% YoY
|
60.00M
58.59M – 61.78M
+26.3% YoY
|
70.35M
70.35M – 70.35M
+17.3% YoY
|
86.03M
83.88M – 88.45M
+22.3% YoY
|
| EPS |
-1.38
est: -1.64 (+16.0%)
|
-1.71
est: -1.82 (+6.1%)
|
-2.18
est: -2.20 (+0.8%)
|
-1.86
est: -2.07 (+10.1%)
|
-1.13
est: -1.37 (+17.3%)
|
-1.67
est: -1.79 (+6.5%)
|
-1.37
est: -1.32 (-3.7%)
|
-0.89
est: -0.49 (-82.5%)
|
-0.31
est: -0.32 (+3.1%)
|
-0.95
est: -0.63 (-51.3%)
|
-0.68
est: -0.61 (-10.7%)
|
-0.38
est: -0.48 (+20.2%)
|
-0.39
est: -0.38 (-3.3%)
|
-0.21
est: -0.14 (-46.9%)
|
-0.25
est: -0.27 (+9.0%)
|
-0.30
est: -0.27 (-13.2%)
|
-0.15
est: -0.09 (-61.7%)
|
0.11
est: 0.09 (+26.7%)
|
-0.22
est: -0.20 (-11.4%)
|
-0.08
est: -0.06 (-36.9%)
|
0.23
est: 0.23 (+1.6%)
|
-0.41
est: -0.18 (-124.9%)
|
-1.63
est: -1.41 (-15.8%)
|
-0.42
est: -0.45 (+5.9%)
|
-0.27
est: -0.29 (+6.5%)
|
-0.11
-0.21 – -0.02
+60.6% YoY
|
0.12
0.07 – 0.17
+201.0% YoY
|
0.38
0.37 – 0.39
+229.1% YoY
|
0.44
0.43 – 0.46
+16.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-20.26M
OE per share TTM
-0.19
Owner's Yield
-3.05%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
71.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Militia Long/Short Equity ETF ORR | 1.29% | 1.79M | 14.19% |
| 2 | Amundi Prime UK Mid & Small Cap UCITS ETF DR - GBP (D) PRUK.L | 0.26% | 1.12M | 0.05% |
| 3 | Xtrackers FTSE 250 UCITS ETF 1D XMCX.L | 0.17% | 63.4K | 0.15% |
| 4 | Vanguard FTSE 250 UCITS ETF (GBP) Distributing VMID.DE | 0.16% | 4.30M | 0.10% |
| 5 | Vanguard FTSE 250 UCITS ETF VMIG.MI | 0.16% | 4.30M | 0.10% |
| 6 | Invesco FTSE 250 UCITS ETF S250.L | 0.16% | 56.3K | 0.12% |
| 7 | iShares FTSE 250 UCITS ETF MIDD.L | 0.16% | 1.34M | 0.40% |
| 8 | HSBC FTSE 250 UCITS ETF HMCX.L | 0.15% | 100.6K | 0.09% |
| 9 | iShares MSCI United Kingdom Small-Cap ETF EWUS | 0.13% | 52.1K | 0.59% |
| 10 | iShares MSCI UK Small Cap UCITS ETF CUKS.L | 0.13% | 162.8K | 0.58% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-39.5K
Shares Outstanding
120.92M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Frank Mathias | Chief Executive Officer & Director | 2M | — |
| Lucinda Crabtree | Chief Financial Officer & Director | 992.0K | — |
| Kyriacos Mitrophanous | Chief Information Officer | — | — |
| Lisa Doman | Chief People Officer | — | female |
| Mark Caswell | Site Head of UK Operations | — | male |
| Natalie Louise Walter | Chief Legal Officer & Company Secretary | — | female |
| Sebastien Ribault | Chief Business Officer | — | — |
| Sophia Bolhassan | Head of Investor Relations | — | female |
| Stephanie Colloud | Site Head & GM of France Operations | — | female |
| Kati Hudson | Head of Intellectual Property and Contracts | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OXB.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
